Tzu‐Hua Chang

610 total citations
13 papers, 469 citations indexed

About

Tzu‐Hua Chang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tzu‐Hua Chang has authored 13 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Tzu‐Hua Chang's work include Lung Cancer Treatments and Mutations (6 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (4 papers). Tzu‐Hua Chang is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer-related molecular mechanisms research (5 papers) and MicroRNA in disease regulation (4 papers). Tzu‐Hua Chang collaborates with scholars based in Taiwan and Hong Kong. Tzu‐Hua Chang's co-authors include Jin‐Yuan Shih, Shang‐Gin Wu, Meng‐Feng Tsai, Yinan Liu, James Chih‐Hsin Yang, Tzu‐Hsiu Tsai, Pan‐Chyr Yang, Chien‐Hung Gow, Shwu‐Bin Lin and Cheng-Po Huang and has published in prestigious journals such as International Journal of Cancer, Life Sciences and Cancer Letters.

In The Last Decade

Tzu‐Hua Chang

13 papers receiving 460 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tzu‐Hua Chang Taiwan 10 297 223 193 129 40 13 469
Xiangyun Zong China 10 252 0.8× 201 0.9× 133 0.7× 77 0.6× 26 0.7× 35 449
Piyada Sitthideatphaiboon Thailand 8 232 0.8× 128 0.6× 129 0.7× 116 0.9× 30 0.8× 24 379
Yabing Zheng China 11 233 0.8× 207 0.9× 143 0.7× 90 0.7× 22 0.6× 40 425
Alissa Poteete United States 8 244 0.8× 134 0.6× 213 1.1× 155 1.2× 68 1.7× 19 450
Kate Lynn J. Bill United States 8 253 0.9× 164 0.7× 117 0.6× 147 1.1× 24 0.6× 10 396
Ngoc T. Hoang United States 6 274 0.9× 130 0.6× 155 0.8× 200 1.6× 22 0.6× 8 467
Masha Huang China 12 377 1.3× 238 1.1× 88 0.5× 89 0.7× 24 0.6× 23 478
Shoujie Chai China 10 239 0.8× 143 0.6× 204 1.1× 109 0.8× 42 1.1× 12 431
Meisongzhu Yang China 12 386 1.3× 220 1.0× 104 0.5× 114 0.9× 63 1.6× 16 524
Wolong Zhou China 12 304 1.0× 157 0.7× 96 0.5× 79 0.6× 52 1.3× 21 427

Countries citing papers authored by Tzu‐Hua Chang

Since Specialization
Citations

This map shows the geographic impact of Tzu‐Hua Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tzu‐Hua Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tzu‐Hua Chang more than expected).

Fields of papers citing papers by Tzu‐Hua Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tzu‐Hua Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tzu‐Hua Chang. The network helps show where Tzu‐Hua Chang may publish in the future.

Co-authorship network of co-authors of Tzu‐Hua Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Tzu‐Hua Chang. A scholar is included among the top collaborators of Tzu‐Hua Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tzu‐Hua Chang. Tzu‐Hua Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Chen, Yi‐Ling, Yinan Liu, Yen‐Ting Lin, et al.. (2023). LncRNA SLCO4A1-AS1 suppresses lung cancer progression by sequestering the TOX4-NTSR1 signaling axis. Journal of Biomedical Science. 30(1). 80–80. 14 indexed citations
2.
Tsai, Tzu‐Hsiu, Chien‐Hung Gow, Meng‐Feng Tsai, et al.. (2023). MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis. Cancer Medicine. 12(13). 14511–14525. 6 indexed citations
3.
Wu, Shang‐Gin, Tzu‐Hua Chang, Meng‐Feng Tsai, et al.. (2023). miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44. Molecular Therapy — Nucleic Acids. 35(1). 102091–102091. 12 indexed citations
4.
Liu, Yinan, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, & Jin‐Yuan Shih. (2023). CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway. Life Sciences. 336. 122345–122345. 6 indexed citations
5.
Liu, Yinan, Meng‐Feng Tsai, Shang‐Gin Wu, et al.. (2020). miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway. Molecular Therapy — Nucleic Acids. 22. 471–483. 38 indexed citations
6.
Lo, Woo-Kuen, et al.. (2020). SAT-024 GLOMERULONEPHRITIS INDUCED BY COMBINATION IMMUNOTHERAPY AND VEGF INHIBITION WITH TYROSINE KINASE INHIBITORS (TKI). Kidney International Reports. 5(3). S12–S12. 2 indexed citations
7.
8.
Wu, Shang‐Gin, Tzu‐Hua Chang, Yinan Liu, & Jin‐Yuan Shih. (2019). MicroRNA in Lung Cancer Metastasis. Cancers. 11(2). 265–265. 59 indexed citations
9.
Wu, Shang‐Gin, Tzu‐Hua Chang, Meng‐Feng Tsai, et al.. (2019). IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer. Cancers. 11(1). 36–36. 18 indexed citations
10.
Tsai, Meng‐Feng, Shang‐Gin Wu, Tzu‐Hua Chang, et al.. (2019). Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer. International Journal of Cancer. 145(6). 1609–1624. 42 indexed citations
11.
Chang, Tzu‐Hua, Meng‐Feng Tsai, Chien‐Hung Gow, et al.. (2017). Upregulation of microRNA-137 expression by Slug promotes tumor invasion and metastasis of non-small cell lung cancer cells through suppression of TFAP2C. Cancer Letters. 402. 190–202. 51 indexed citations
12.
Liu, Yinan, Tzu‐Hua Chang, Meng‐Feng Tsai, et al.. (2015). IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget. 6(12). 10415–10431. 64 indexed citations
13.
Huang, Cheng-Po, Meng‐Feng Tsai, Tzu‐Hua Chang, et al.. (2012). ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Letters. 328(1). 144–151. 129 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiangyun Zong Breakdown of academic impact, for papers by Piyada Sitthideatphaiboon Breakdown of academic impact, for papers by Yabing Zheng Breakdown of academic impact, for papers by Alissa Poteete Breakdown of academic impact, for papers by Kate Lynn J. Bill Breakdown of academic impact, for papers by Ngoc T. Hoang Breakdown of academic impact, for papers by Masha Huang Breakdown of academic impact, for papers by Shoujie Chai Breakdown of academic impact, for papers by Meisongzhu Yang Breakdown of academic impact, for papers by Wolong Zhou
Rankless by CCL
2026